Wikipedia -WSS

Wikipedia

author：explore 2025-10-01 20:14:44 - browse：3

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： FDA approves updated Covid vaccines

WSS

How to make the FDA’s new prescription one

Primary care doctor shortage won't be solved by free med school tuition

AI for drug discovery: Experts on separating hype from reality

Acelyrin, a rare IPO success, stumbles in its first big test

Deliver public health messages at the right time

HHS's proposed rule does nothing to address the climate crisis

Wikipedia

Wikipedia

leisure time

New air purifier tech could be key to improving indoor air quality

PBM executives asked to testify by House panel

The high cost of giving birth even with insurance

How housing is health care on Long Island

23andMe had bad news about my health. I wish a person had delivered it

Most antidepressants don't work on kids, teens, study finds

Cancer drug shortages should be causing more outrage

Generate Biomedicines machine learning biotech raises $273M

DIEP, the 'gold standard' of breast reconstruction, is under threat

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

focus

Will the IRA bring competition to the biologics market?

Is it ever OK for doctors to lie to their patients?

Food makers to regulators: Ultra

As health system earnings go up, health insurance stocks go down

Food makers tried to stack nutrition panel with preferred experts

Generate Biomedicines machine learning biotech raises $273M

entertainment

explore

knowledge

focus